AbCellera ABCL635 Phase 2 Results Lift Shares
AbCellera ABCL635 Phase 2 Results showed the drug met primary endpoints cutting hot flash frequency and severity and prompting a 24% stock rise.
KEY TAKEAWAYS
- ABCL635 cut VMS frequency 83% vs 33% and severity 58% vs 12% at week 4.
- ABCL635 was well tolerated over four weeks with no serious or severe adverse events.
- Shares rose 24% following the release.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
AbCellera Biologics Inc. said in a press release on Aug. 10, 2026, that its investigational NK3R (neurokinin 3 receptor) antagonist antibody ABCL635 produced large reductions in vasomotor symptom frequency and severity at week 4 after a single dose. The stock rose 24% in premarket trading.
Phase 2 Efficacy Results
The Phase 2 portion of the Phase 1/2 trial met its primary efficacy endpoints with statistically significant reductions in both frequency and severity of vasomotor symptoms compared with placebo at week 4. The mean reduction in moderate-to-severe vasomotor symptom frequency was 8.8 events per day for ABCL635 versus 3.5 for placebo, a placebo-adjusted difference of 5.3 events (p<0.001). The mean percent reduction in frequency was 83% for ABCL635 versus 33% for placebo.
Severity also declined significantly. The mean reduction in vasomotor symptom severity was 1.4 points for ABCL635 versus 0.3 for placebo, a placebo-adjusted difference of 1.1 points (p<0.001). The mean percent reduction in severity was 58% for ABCL635 versus 12% for placebo. The company reported additional improvements in sleep and patient global impression of change, linking these outcomes to the broader hot-flash reduction observed.
Safety and Trial Design
ABCL635 is a non-hormonal menopause treatment being studied for moderate-to-severe vasomotor symptoms. The trial was a multicenter, randomized, double-blind, placebo-controlled study involving approximately 80 postmenopausal women. It represents the Phase 2 portion of a Phase 1/2 program, identified by trial number NCT07118891.
Over the four-week period, ABCL635 was well tolerated with no serious or severe adverse events and no discontinuations due to adverse events. The most common side effects were headache, fatigue, and injection-site reactions.
Following the topline release, AbCellera’s stock rose 24% in premarket trading. The company did not provide formal revenue or earnings guidance linked to ABCL635 but said the Phase 2 results support continued development. The press release did not include a detailed development timeline or regulatory filing plan.
